Medical Imaging Technologies for Oncology Diagnostics: The Global Market

Report Highlights

The global market for diagnostic imaging equipment for oncology reached more than $11.6 billion in 2010 and, despite the global recession, is forecast to grow to about $14.8 billion by 2015, an overall compound annual growth rate (CAGR) of 5% for 2010 through 2015.

SCOPE OF REPORT

Oncology diagnostic imaging products designate hardware, software, and supplies used to create, view, and manage visual images of nonvisible organs of the human body for purposes of diagnosing cancer.  The report focuses on end-user markets, including hospitals, freestanding clinics, doctors’ offices, and equipment leasing companies.

The following well-established technologies are includedin the study: flat panel display (FPD) products such as computed radiography (CR), x-ray, including analog and digital x-ray; magnetic resonance imaging (MRI), including standard MRI and functional MRI or MR fluoroscopy; computed tomography (CT), including standard CT, multislice or ultrafast CT, and electron beam tomography; single photon emission computed tomography (SPECT); positron emission tomography (PET); ultrasound; and endoscopy, including fiber-optic endoscopy, video endoscopy, and ingestible cameras.  In the last few years, several multimodal products have been developed in an attempt to combine the advantages of structural and functional imaging.  Multimodal combinations currently on the market include CT/SPECT; PET/CT; MRI/MSI; and endoscopic ultrasound (EUS), combining fiber-optic endoscopy and ultrasound.  Nearly 100% of all PET sales today are in the form of combination PET/CT imaging systems; therefore, this report addresses the market for PET/CT oncology diagnostics systems rather than PET standalone systems.

New and emerging technologies that may become commercially significant by 2015 are also addressed in this report.  These include contrast-enhanced ultrasound, subharmonic breast ultrasound, whole-breast ultrasound tomography, radiation luminescence and radioactive optical nano-imaging techniques, near-infrared fluorescent imaging, near-infrared (NIR) optical coherence tomography, supersonic shear imaging (SSI), microwave tomography, cone beam CT, digital breast tomosynthesis (DBT), single-shot spectral imaging (SSSI) for mammography, breast-specific gamma imaging (BSGI), and photoacoustic tomography (PT).  The latest development in combination imaging is PET/MR, now being introduced by Siemens, Philips, and GE.

Products used for radiotherapy, dentistry, nonmedical imaging (e.g., in physics, chemistry, geology, and industry), and veterinary medicine are excluded from the study.

ANALYST CREDENTIALS

The analyst has an undergraduate degree in biology and graduate degrees in business administration and master’s of science in business.  In addition, the analyst has over a decade of experience in marketing, market research, and business development in medical devices, diagnostics, and pharmaceuticals in the U.S. and Europe.